MEGIN announced today Le Bonheur Children’s Hospital is the first hospital in the world to install TRIUX neo, the next generation of magnetoencephalography (MEG) technology for functional brain imaging.
A highly sensitive, non-invasive method for mapping the human brain, TRIUX neo is used to assess complex neurological disorders.
TRIUX neo can detect and localize neural events that are generated in the brain with millimeter accuracy and millisecond resolution.
“Le Bonheur Children’s has a world-class neuroscience program. They are leaders in implementing innovative technologies that translate to better care and improved outcomes,” said Janne Huhtala, CEO of MEGIN. “We are honored to be working with their amazing team of clinicians and researchers as we look to expand the clinical impact of our technology.”
When this information is merged with structural MRI imaging, it provides a view to critical areas of the brain such as those areas responsible for the ability to see, talk, or move. Using this kind of information can confirm a diagnosis when other imaging modalities are inconclusive, thereby increasing the accuracy of surgical intervention and minimizing risk of neurological deficit.
“We provide excellent care to children with neurologic diagnoses using advanced technology, clinical expertise and state-of-the-art facilities. As one of the nation’s best pediatric neuroscience programs according to U.S. News & World Report, we are looking forward to incorporating this new technology,” said James Wheless, MD, chief of Pediatric Neurology for the University of Tennessee Health Science Center and co-director of Le Bonheur’s Neuroscience Institute.
Le Bonheur Children’s Hospital in Memphis, Tenn., treats children each year through community programs, regional clinics and a 255 bed state-of-the-art hospital. Le Bonheur serves as a primary teaching affiliate for the University Tennessee Health Science Center and trains more than 350 pediatricians and specialists each year. Nationally recognized, Le Bonheur is ranked by U.S. News & World Report as a Best Children’s Hospital.
“Using MEG, we determine the focus of seizures and can map sensory and motor areas,” said Frederick Boop, MD, chair of the Department of Neurosurgery for the University of Tennessee Health Science Center and co-director of the Neuroscience Institute. “This has allowed us to perform brain surgery in children more safely and with fewer complications. It has also allowed us to extend our surgical capabilities in children with epilepsy to those who might not have been recognized as surgical candidates in the past. This new technology will help us continue this important work.”
Based in Helsinki, Finland for over 29 years, MEGIN has been the leading manufacturer of magnetoencephalography (MEG) technology for functional brain imaging used for presurgical evaluation of epilepsy, brain tumors, or other lesions, and surgical planning for localization of sensory information.
TRIUX neo, a fourth-generation system, the most recent technology to be introduced, has been developed to support medical professionals in the delivery of quality care and improved outcomes.
In July 2018, MEGIN was acquired by York Instruments, forming the new global leader of functional brain imaging technology.
For more information contact: Tyler Lecceadone – firstname.lastname@example.org – 616-776-3511